Cancer Genetics Announces Acquisition of NovellusDx to Expand its Oncology Platform

 Cancer Genetics Announces Acquisition of NovellusDx to Expand its Oncology Platform

Cancer Genetics Announces Acquisition of NovellusDx to Expand its Oncology Platform

Shots:

  • Cancer Genetics is acquiring NovellusDx by paying equity of ~49% in Cancer Genetics. NovellusDx will also provide $2. 3M bridge loan to Cancer Genetics
  • Cancer Genetics will get hold of NovellusDx’s technology and machine learning capabilities for development of oncology drugs
  • The acquisition will strengthen the focus on oncology precision medicines, and developing targeted therapeutics in cancer treatment. The transaction is expected to close in H1’19

Click here to read full press release/ article | Ref: Cancer Genetics | Image: Novellus_Businesswire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post